Bladder cancer cells on a pink background

KEYNOTE-905: A practice-changing trial?

Last updated: 30th Oct 2025

Published: 30th Oct 2025

“This is a remarkably important study.” Neal Shore discusses the efficacy and safety findings of the KEYNOTE-905 trial in muscle-invasive bladder cancer. View transcript.

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information

Name

Email address

Specialty

By providing your email address, you are opting in to receive our monthly newsletter.

Opt-in: By selecting this box, I consent to receiving marketing communications and information about Medthority's resources by email.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.

Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.